Shares in Bruker Decline 11 Percent After Firm Said Material Weakness Will Raise 04 Losses

Mar 16, 2005

NEW YORK, March 16 (GenomeWeb News) - Shares in Bruker Biosciences were down more than 11 percent, or $.44, at $3.51 in mid-afternoon trading after the firm said that its 2004 net losses, reported on March 2, would likely increase following internal audits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Synthetic Genomics Sued for Gender Discrimination

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Football Team's DNA Day Postponed

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

This Week in Cell

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Main menu